BOSTON--(BUSINESS WIRE)--(Click to Tweet)- Flex Pharma, Inc., a biopharmaceutical company that is developing innovative and proprietary treatments for nocturnal leg cramps and other severe neuromuscular conditions, today announced that Marc Kozin and Stuart Randle have joined the company's Board of Directors.
“With their breadth and depth of experience in healthcare, Marc and Stu will provide a tremendous resource as we endeavor to develop solutions for patients with severe neuromuscular disorders,” commented Flex Pharma Co-Founder, Co-Chair of the Company’s Scientific Advisory Board and Nobel Laureate, Rod MacKinnon, M.D.
Mr. Kozin brings more than three decades of experience in strategy consulting and deep industry expertise advising biopharmaceutical, life sciences and med-tech companies. He is a Senior Advisor to L.E.K. Consulting, a global strategy consulting firm, and the former President of the North American practice, which he led for 15 years. Mr. Kozin received his M.B.A. from The Wharton School and his B.A. from Duke University.
As a seasoned executive with more than 25 years of experience in the life sciences industry, Mr. Randle most recently served as President and Chief Executive Officer of GI Dynamics from 2004 to 2014. Previously, he served as President and Chief Executive Officer at ACT Medical. Prior to ACT, Mr. Randle was Corporate Officer at Allegiance Healthcare Corporation. He started his career at Baxter Healthcare, where he spent 10 years in various senior management positions. Mr. Randle holds an M.B.A. from The Kellogg Graduate School of Management and a B.S. from Cornell University.
“These appointments further strengthen our Board with expertise across key facets of the healthcare industry. I look forward to working with Marc and Stu and tapping into their industry knowledge," said Flex Pharma Chairman and Chief Executive Officer Christoph Westphal, M.D., Ph.D.
Also on the Board of Directors of Flex Pharma are John Sculley, former Apple CEO and PepsiCo President; Peter Barton Hutt, former General Counsel of the U.S. Food and Drug Administration; Steve Kraus, Partner of Bessemer Venture Partners; and Dr. Westphal, Chairman and Chief Executive Officer of Flex Pharma.
About Flex Pharma
Flex Pharma, Inc. is a biopharmaceutical company that is developing innovative and proprietary treatments for nocturnal leg cramps and other severe neuromuscular conditions. In randomized, blinded, placebo-controlled studies, Flex Pharma's proprietary treatment has shown a statistically significant reduction in the intensity of muscle cramps in healthy normal volunteers. In the second quarter of 2015, the Company intends to initiate at least one human proof-of-concept study of its proprietary treatment for individuals with nocturnal leg cramps.
Flex Pharma was founded by National Academy of Science members Rod MacKinnon, M.D. (2003 Nobel Laureate), and Bruce Bean, Ph.D., recognized leaders in the fields of ion channels and neurobiology, along with Chairman and Chief Executive Officer Christoph Westphal, M.D., Ph.D. Flex Pharma is backed by the Longwood Fund, Bessemer Venture Partners, EcoR1 Capital, Jennison Associates, LLC and a number of additional blue chip investment funds and angels.
